Summary
Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on August 9, 2017, to announce its financial results for the second quarter ended June 30, 2017. The key takeaway from this filing is the company's adherence to reporting its quarterly financial performance, with specific details contained within the furnished press release (Exhibit 99.1). While this 8-K primarily serves as a notification of the earnings release and does not provide detailed financial figures within the report itself, it signifies that investors should refer to the accompanying press release for comprehensive insights into ALNY's operational and financial condition for the period. This is a standard procedural filing for publicly traded companies to ensure timely dissemination of financial information to the market.
Key Highlights
- 1Alnylam Pharmaceuticals, Inc. announced its financial results for the quarter ended June 30, 2017.
- 2The announcement was made via a press release furnished as Exhibit 99.1 to the Form 8-K.
- 3The filing is a procedural update related to Item 2.02 (Results of Operations and Financial Condition).
- 4The information furnished under Item 2.02 is not deemed 'filed' for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings unless specifically stated.
- 5Exhibit 99.1 contains the full text of the press release detailing the financial results.
- 6The report was signed by Manmeet S. Soni, Senior Vice President, Chief Financial Officer, on August 9, 2017.